

Transforming Healthcare with Nanomedicine: A SWOT Analysis of Drug Delivery Innovation

Hao Zhang¹, Suping Li¹, Xingming Ma²

¹Department of Nuclear Medicine, Affiliated Hospital of North Sichuan Medical College North Sichuan Medical College, Nanchong, 637000, People's Republic of China; ²School of Health Management, Xihua University, Chengdu, 610039, People's Republic of China

Correspondence: Hao Zhang, Department of Nuclear Medicine, Affiliated Hospital of North Sichuan Medical College, North Sichuan Medical College, Nanchong, 637000, People's Republic of China, Tel +86-0817-2242705, Email zhanghao_112_sh@126.com

Objective: Nanomedicine represents a transformative approach in biomedical applications. This study aims to delineate the application of nanomedicine in the biomedical field through the strengths, weaknesses, opportunities, and threats (SWOT) analysis to evaluate its efficacy and potential in clinical applications.

Methods: The SWOT analysis framework was employed to systematically review and assess the internal strengths and weaknesses, along with external opportunities and threats of nanomedicine. This method provides a balanced consideration of the potential benefits and challenges.

Results: Findings from the SWOT analysis indicate that nanomedicine presents significant potential in drug delivery, diagnostic imaging, and tissue engineering. Nonetheless, it faces substantial hurdles such as safety issues, environmental concerns, and high development costs. Critical areas for development were identified, particularly concerning its therapeutic potential and the uncertainties surrounding long-term effects.

Conclusion: Nanomedicine holds substantial promise in driving medical innovation. However, successful clinical translation requires addressing safety, cost, and regulatory challenges. Interdisciplinary collaboration and comprehensive strategic planning are crucial for the safe and effective application of nanomedicine.


Keywords: nanomedicine, drug delivery systems, SWOT analysis, biomedical application, safety, interdisciplinary collaboration

Introduction


Nanomedicine, based on nanotechnology, enhances the diagnosis, treatment, and management of diseases. It offers significant advantages such as precisely targeted delivery, reduced side effects, and improved bioavailability, demonstrating its vital role in cancer therapy and other medical fields¹ (Figure 1). The term “nanomedicine” encompasses a range of specially designed nanoscale drug delivery systems targeted towards different cells and tissues within the body.² This precise targeting aids in the more efficient delivery of drugs and reduces side effects, making nanomedicine a prominent alternative to traditional drugs.³

The application of nanotechnology principles in nanomedicine has revolutionized the management of diseases, providing targeted delivery systems that enhance drug efficacy and reduce side effects.⁴ Recent research advancements have highlighted its crucial role in cancer treatment, where nanomaterials have shown the potential to deliver therapeutic drugs directly to tumor sites and enhance treatment effectiveness.⁵ Emerging strategies involving prodrugs and nanomedicines underscore innovative approaches to enhance gemcitabine-based therapies, indicating significant progress in cancer treatment methods.⁶ For the advancement of human medical applications, the development and optimization of nanoparticles (NPs) for therapeutic purposes are crucial, emphasizing the importance of nanotechnology in drug delivery systems.⁷ Furthermore, nanomedicine exhibits the capability to encapsulate and improve the solubility of pharmacologically active compounds (such as quercetin) to enhance oral bioavailability, representing a significant step forward in overcoming traditional drug delivery challenges.^{8,9} This comprehensive approach to the development and application of


Fundamentals of Nanomedicine




Drug delivery and targeting mechanisms



Application of Nanoparticles



Increased bioavailability



Advantage, challenge and future directions



Figure 1 Overview of Nanomedicine Development, Mechanisms, and Therapeutic Applications. The fundamentals of nanomedicine are depicted, including various forms such as inorganic NPs, liposomes, and polymers. It illustrates the drug delivery and targeting mechanisms, highlighting the enhanced permeability and retention (EPR) effect, the ability to cross the blood-brain barrier, and the process of endocytosis. The figure also showcases the diverse applications of nanomedicine in medical fields, the improvements in bioavailability, and discusses the advantages, challenges, and future directions for nanomedicine.

nanomedicine showcases their potential in addressing complex therapeutic needs and paves the way for future innovations in medical science.

Compared to traditional drugs, nanomedicine demonstrates superior efficacy and fewer adverse reactions, largely attributed to its small size and targeted delivery characteristics.¹⁰ In recent years, there has been an increasing inclination towards the clinical application of nanomedicine. A key advantage of these drugs is their small size. NPs typically range between 10 and 1000 nm, with sizes below 200 nm being particularly effective in the biomedical field.¹¹ This size range utilizes enhanced permeability and retention (EPR) effects for effective passive targeting, allowing NPs to selectively accumulate in diseased tissues or organs, thereby enhancing drug efficacy.¹²

Additionally, the small size of NPs enables them to traverse biological barriers, such as the longstanding challenge of the blood-brain barrier in drug delivery.¹³ These particles can be directly internalized by target cells, thereby enhancing efficacy and reducing side effects.¹⁴ Another notable characteristic of nanomedicine is its ability to improve drug solubility and pharmacokinetics.^{4,15} Many drugs suffer from poor solubility, impacting their effectiveness. Nanomedicine addresses this issue by encapsulating drugs in NPs, thereby enhancing their solubility and bioavailability.¹⁶ Furthermore, the addition of specific ligands onto NPs can enhance their selectivity, reducing off-target effects.¹⁷

The classification of NPs is based on various factors, including composition, size, morphology, and surface charge.¹⁸ The choice of NP composition is crucial for drug delivery, affecting the stability, release characteristics, and biocompatibility of nanomedicine.^{19,20} Similarly, the size and morphology of NPs may influence their distribution within the body, cellular uptake, and toxicity.^{21–23} The surface charge of NPs plays a vital role in their interaction with biological systems and their ability to penetrate biological barriers.^{24,25}

The strengths, weaknesses, opportunities, and threats (SWOT) analysis method provides a systematic and structured approach, helping organizations to comprehensively understand their situation and make necessary adjustments and improvements. Previous analyses using SWOT in the context of nanomedicine have been limited, with the focus primarily on “the role of nanomedicine in drug delivery”.²⁶ This study, however, demonstrates the broad applications and key outcomes of nanomedicine across various medical fields, including drug delivery, diagnostic imaging, tissue engineering, and their clinical translation. Additionally, we identify major challenges in the development of nanomedicine, such as safety concerns and high costs, and offer recommendations for interdisciplinary collaboration and comprehensive strategic planning to further advance the field.

Analysis Based on SWOT Framework

Recent advancements in implementation research have highlighted the importance of quantitative methods in evaluating the efficacy of clinical solutions.²⁷ The diversity in selecting implementation strategies has underscored the necessity to address contextual barriers, ensuring the tailored application of scientific findings in clinical settings.²⁸ Furthermore, the application of theory in implementation research has offered valuable clarity.²⁹ It provides a conceptual framework for research in clinical decision support systems, highlighting the necessity for systematic and precise evaluation methods.³⁰

Strategic analysis has long held a significant position in corporate strategy and is now increasingly recognized in the scientific research field, particularly in biomedicine. This methodological approach, especially when shaped within the SWOT framework, can significantly enhance the efficiency and effectiveness of translating scientific breakthroughs into clinical solutions.

Biomedical research often faces the challenge of balancing the demands for innovative scientific discoveries with the practical needs of clinical applications. In this regard, the SWOT framework serves as a key tool. It enables researchers to systematically assess how scientific advancements may impact clinical outcomes, focusing on internal strengths and weaknesses of the research, as well as external opportunities and threats. This comprehensive approach ensures a balanced consideration of the potential for discoveries and challenges.

In the field of biomedical research, the path from the laboratory to clinical practice is often complex and resource-intensive, and SWOT analysis can offer valuable insights. It aids in evaluating the feasibility of clinical solutions, involving factors such as resource allocation, regulatory compliance, market demands, and ethical implications.

Researchers can make more informed decisions by identifying potential risks and returns to optimize their efforts and resources.

The SWOT analysis method offers a systematic approach for the biomedical field to evaluate its internal and external environments, guiding strategic decision-making, planning, and resource allocation. This approach helps foster continuous development and innovation in the biomedical field. Based on SWOT analysis, decision-makers can assess the strengths, weaknesses, opportunities, and threats associated with new technologies, drugs, or therapies in the biomedical domain.³¹ It helps identify internal strengths and weaknesses while considering external opportunities and threats, facilitating the formulation of more targeted and effective research strategies and directions.³² For biomedical enterprises, SWOT analysis reveals product strengths and weaknesses, identifies market opportunities, and recognizes competitive threats, aiding in rational planning. In drug development and marketing, SWOT analysis can assist in formulating appropriate product promotion plans and evaluating market demands and potential risks. Healthcare institutions can utilize SWOT analysis to assess internal operational strengths and weaknesses, seize external opportunities, and prevent potential threats, thereby enhancing service quality and efficiency.^{33,34}

For instance, in the emerging field of nanomedicine, SWOT analysis may be particularly crucial. Nanomedicine has made significant advancements in the pharmaceutical sector by enhancing drug efficacy, reducing side effects, and enabling targeted delivery. However, the field also faces challenges such as safety issues, environmental impacts, and high research and development costs. SWOT analysis in such situations can unravel these complexities, identifying strengths like the potential for targeted treatment, weaknesses such as the unknown long-term effects of nanomedicine, opportunities that may include expanding into untapped therapeutic areas, and threats that could involve regulatory hurdles or public skepticism.

Based on the SWOT framework, researchers can strategically navigate the complex nanomedicine development domain. This analysis aids in identifying areas for improvement and growth and in formulating robust strategies and contingency plans. This structured approach, while fostering innovation, ensures the practicality and ethical integrity of biomedical research, signifying its profound significance.

In conclusion, strategic analysis, particularly through the perspective of the SWOT framework, is an indispensable tool for biomedical researchers (Figure 2). It offers a comprehensive approach to evaluating the impact and feasibility of new treatments and therapies. In the increasingly complex landscape of biomedical research, such tools are crucial in guiding scientists through the process of translating scientific discoveries into practical clinical solutions.

Strengths: Revolutionary Advances of Nanomedicine in Drug Delivery

In the current intersection of medicine and technology, the rapid development of nanotechnology has provided unprecedented therapeutic opportunities. Nanomedicine, particularly the research and application of nanodrugs, is at the forefront of this revolution. Nanodrugs leverage their unique physicochemical properties to overcome the limitations of traditional drugs in terms of safety, efficacy, and targeting, paving the way for new treatment avenues. This review delineates the advantages of nanodrugs over traditional drugs and how they are revolutionizing current medical practices. Nanodrugs are categorized according to their material types, including carbon-based NPs, liposomes, metal NPs, dendritic polymers, polymer micelles, polymer NPs, and nanocrystals. The review examines their characteristics, application areas, and impact on the future of healthcare (Figure 3). These nanodrugs demonstrate significant advantages in drug delivery, treatment efficacy, and targeting, heralding a new era in medical therapy. With further research, nanodrugs are expected to play an increasingly important role in enhancing effectiveness, reducing toxicity, and improving patients' quality of life.

Carbon-Based NPs

Carbon-based NPs have been highly praised for their exceptional properties, such as high stability, aspect ratio, and sensitivity. These NPs, in various forms like carbon nanotubes, graphene, and diamond, exhibit unique advantages in diverse applications such as catalysis, gene delivery, environmental remediation, and biosensors.³⁵ In particular, carbon nanotubes have emerged as leaders in drug delivery applications. Their ability to bind drug molecules to their sidewalls through non-covalent or covalent methods has paved a new path for targeted drug delivery systems. This innovation can




Figure 2 SWOT Analysis of Nanomedicine Development: Strategies from Laboratory to Clinical Application. The strengths section emphasizes the precision of drug delivery and the effectiveness of targeted therapy. The weaknesses section addresses the technical complexities, potential hazards, and high costs associated with nanomedicine. Opportunities are highlighted, noting the increasing medical needs and expanding market demand for nanomedicine technologies. Finally, the threats section identifies regulatory challenges, market acceptance issues, and competition as significant hurdles to be overcome in the development of nanomedicine.

revolutionize drug administration, enhancing therapeutic effects while reducing side effects.³⁶ Furthermore, the emergence of graphene oxide NPs as a new member of the carbon-based nanomaterial family has opened avenues for developing advanced anti-cancer therapies and diagnostic imaging agents. With high drug loading capacity and unique physicochemical properties, graphene oxide NPs are ideal candidates for these applications,³⁷ particularly crucial in oncology where targeted delivery and reduced toxicity are paramount. A key aspect worth emphasizing about carbon-based NPs is their biocompatibility, making them suitable for medical applications. For instance, certain carbon nanotubes have been designed to target cancer cells, offering a promising alternative to conventional chemotherapy, thus avoiding unnecessary exposure of healthy cells to cytotoxic drugs.³⁸ This targeted approach proves more effective and significantly mitigates the adverse effects typically associated with cancer treatment. Moreover, the application of carbon-based NPs in biosensors represents a groundbreaking development. These NPs have the potential to detect and monitor various biomolecules and diseases, potentially revolutionizing the diagnostic process in the healthcare sector.³⁹ The sensitivity and accuracy of these biosensors may lead to early disease detection, thereby improving patient outcomes. Thus, the outstanding properties and versatility of carbon-based NPs position them as a key research area with immense innovation potential. Their multifaceted applications in medicine, energy, electronics, and other fields signal the onset of a new technological era that could profoundly impact and enhance various aspects of human life. As research in this field




Figure 3 Applications of Nanomedicine in Medical Fields. This figure describes the unique properties and uses of different types of NPs, including carbon-based NPs known for their high stability, aspect ratio, sensitivity, and biocompatibility. Liposomes are highlighted for their precise targeting capabilities, delivery specificity, efficacy, and their use in cancer and gene therapy. The figure also details the applications of metal NPs in drug delivery, imaging, and biosensing due to their biocompatibility and degradability. Additionally, it covers dendrimers, polymeric micelles, polymeric NPs, and nanocrystals, emphasizing their roles in targeted drug delivery, enhanced solubility of drugs, and other therapeutic and diagnostic applications.

continues to evolve, we anticipate that carbon-based NPs will play a central role in advancing scientific knowledge and practical applications in the future.

Liposomes

Liposomes, known for their outstanding versatility and therapeutic efficacy, stand at the forefront of drug delivery technology. This technology, renowned for its ability to transport a variety of therapeutic agents, spans a wide range, including small-molecule drugs, proteins, peptides, and genetic materials, making liposomes an indispensable tool in

modern medical research. The unique functionality of liposomes, allowing for encapsulation of both hydrophilic and hydrophobic drugs within the same structure, further solidifies their position as efficient and versatile delivery systems.⁴⁰

The composition of liposomes is particularly noteworthy. They consist of a phospholipid bilayer that forms a spherical structure with hydrophilic heads and hydrophobic tails, setting them apart from other NPs of the same general type. This arrangement encloses an aqueous core, ideal for hydrophilic drugs, while the lipid bilayer can accommodate hydrophobic drugs.⁴¹ Such a design protects the encapsulated drugs from degradation and enzymatic breakdown and enhances their stability and bioavailability. Liposomes ensure drug delivery to target sites to prevent premature degradation or metabolism by maintaining the active ingredients.

One significant advantage of liposomes in drug delivery lies in their surface adaptability. By modifying the liposome surface to bind with specific ligands, targeted delivery to particular cells or tissues can be achieved.⁴² This precise targeting ability, through ligand attachment to the liposome surface, significantly enhances delivery specificity and efficacy while reducing the likelihood of adverse reactions in non-target tissues.

The extensive customization potential of liposomes renders them applicable in various drug delivery scenarios. Modifications can be made to their size, charge, and even shape, providing a tailored approach to meet the specific requirements of different drugs.⁴³ This adaptability highlights the potential of liposomes to address a wide range of therapeutic needs, from cancer treatment to gene therapy and beyond.

Therefore, the unique structural features and customizability of liposomes make them a focal point in drug delivery research. Their broad applications in oncology and genetic medicine suggest a future where liposome-based delivery systems could revolutionize therapeutic practices. Continued research and development in this field are expected to further unleash the potential of liposomes, potentially revolutionizing drug delivery methods and significantly enhancing patient outcomes.

Metal NPs

Metal NPs have become a focal point in biomedical research due to their unique physicochemical properties,^{44–46} with particular attention on iron, gold, and silver NPs for their therapeutic and diagnostic potential. Iron NPs exhibit significant superparamagnetic properties, showing excellent responsiveness under a magnetic field,⁴⁷ and are widely utilized in the biomedical field. Superparamagnetic iron oxide NPs (SPIONs) serve as contrast agents for magnetic resonance imaging and targeted drug delivery for various diseases such as cancer, inflammation, and neurological disorders, garnering significant interest. The tendency of SPIONs to accumulate in tumor tissues highlights their crucial value in the diagnosis and treatment of cancer, with their biocompatibility and degradability emphasizing their potential for clinical applications.⁴⁸

Gold NPs have gained widespread attention due to their unique optical properties, particularly surface plasmon resonance (SPR).⁴⁹ This property enables them to efficiently absorb and scatter light in the visible and near-infrared regions, aiding in imaging and photothermal therapy applications.⁵⁰ The efficacy of photothermal therapy has shown promising results, and the small size of gold NPs, along with their ability to be functionalized with tumor-specific ligands, make them a promising choice for targeted drug delivery. Targeted drug delivery methods help enhance the efficacy of chemotherapy and reduce systemic toxicity, representing a significant advancement in cancer treatment.⁵¹

Silver NPs are renowned for their potent antibacterial properties,⁵² with mechanisms including silver ion release, bacterial membrane disruption, and interference with bacterial metabolism, displaying remarkable effectiveness in combating infections.⁵³ Therefore, their application in wound dressings, medical implants, and coatings is crucial for preventing bacterial infections. Furthermore, the unique optical and electrical properties of silver NPs make them suitable for imaging and biosensing applications.⁵⁴

In conclusion, the diverse applications and unique properties of iron, gold, and silver NPs symbolize a new frontier in biomedical research. Their potential in diagnostics, therapeutics, and antimicrobial applications underscore their current value in medical practice and lay the groundwork for future innovations in the medical field. Ongoing research and development will lead to new applications, enhance existing therapeutic outcomes, and drive a revolution in healthcare and patient care.

Dendrimeric Polymers

Dendrimeric polymers, renowned for their highly branched and symmetrical structure, have emerged as a focal point in biomedical research, particularly for their immense potential as drug delivery vehicles. One of their notable features is the ability to selectively target and accumulate in tumor tissues, significantly enhancing their potential in cancer therapy. This targeted accumulation is primarily attributed to the small size of dendrimeric polymers, allowing them to penetrate the abnormally permeable vessels commonly associated with tumors. Additionally, dendrimeric polymers possess the capability to functionalize and enhance the specificity of cancer cells, thereby improving therapeutic efficacy.^{55–59}

A prominent advantage of dendrimeric polymers lies in their capacity to encapsulate drugs within their complex structure. This encapsulation aids in enhancing drug solubility and stability, as well as increasing bioavailability, resulting in more effective treatment outcomes. Furthermore, dendrimeric polymers can protect encapsulated drugs from degradation and systemic clearance, thus extending their therapeutic lifespan.⁶⁰

The drug delivery systems based on dendrimeric polymers offer the advantage of controlling and precisely releasing drugs. By developing stimuli-responsive dendrimeric polymers, a design can be implemented to trigger drug release under specific conditions such as pH or temperature changes. The precision in drug release facilitates targeted and efficient therapy while minimizing potential side effects to a great extent.^{61,62}

Beyond their applications in drug delivery, dendrimeric polymers are also utilized in various other biomedical fields, including gene delivery, imaging, and diagnostics. In gene therapy, dendrimeric polymers serve as efficient non-viral vectors due to their optimal size and structure for cellular uptake and gene transfection.⁶³ In medical imaging, NPs based on dendrimeric polymers have shown potential as contrast agents for MRI and CT scans owing to their high surface area to volume ratio and capability for functionalization with imaging markers.⁶⁴

In conclusion, dendrimeric polymers represent a class of highly versatile and innovative nanomaterials with a broad spectrum of potential biomedical applications. Their unique characteristics, including small size, high surface area to volume ratio, and functionalization capability, position them as potentially revolutionary factors in drug delivery and therapeutic interventions across various medical domains. Continuous research on dendrimeric polymers is expected to yield breakthrough discoveries and advance nanomedicine technologies, paving the way for novel and more effective medical solutions. Additionally, amphiphilic block copolymer micelles formed in aqueous solutions above the critical micelle concentration represent a distinct class of NPs garnering significant attention in the field of drug delivery due to their innovative properties. These micelles exhibit stability, biocompatibility, low immunogenicity, and enhanced solubility for poorly soluble drugs.⁶⁵ The combination of these characteristics makes them a highly promising tool in modern drug therapy.

Polymer Micelles

Polymer micelles offer a key advantage by encapsulating drugs within their hydrophobic cores, effectively shielding them from inactivation *in vivo* and thus enhancing their bioavailability.⁶⁶ This encapsulation ensures more efficient drug delivery to the target site, potentially enhancing therapeutic efficacy. Furthermore, through engineered design, polymer micelles can be specifically targeted to tissues or cells, such as cancer cells. This targeted approach not only enhances therapeutic effects but also reduces off-target effects, marking a significant advancement in cancer treatment.⁶⁷

The versatility of polymer micelles is further demonstrated in their adaptability; they can acquire new functions by incorporating various functional groups.^{68–70} These modifications include adding targeting ligands to guide micelles to specific tissues or cells and imaging agents to monitor micelle distribution *in vivo*. This situation contributes to the development of multifunctional nanocarriers, suitable for both treatment and diagnosis. Additionally, polymer micelles can release drugs under specific triggers such as pH or temperature changes through stimulus-responsive engineering, providing controlled drug release and reducing potential side effects.⁷¹

Another significant advantage is that polymer micelles enhance the solubility of poorly soluble drugs, a critical barrier in drug development.⁷² The hydrophobic core of these micelles effectively solubilizes drugs, facilitating drug delivery to target sites. This property addresses a key challenge in pharmaceutical development, where many potentially effective drugs are abandoned due to solubility issues.

In conclusion, polymer micelles represent a significant breakthrough in the field of drug delivery, with the potential to significantly improve the efficacy and safety of treating various diseases. Continuous research and development are crucial to further enhance the performance of polymer micelles and gain a comprehensive understanding of their pharmacokinetics and pharmacodynamics. With advancements in this field, the future of drug delivery systems appears promising, with polymer micelles emerging as one of the most promising technologies.⁷³

Polymer NPs

NPs have dimensions ranging from 10 to 1000 nm, representing an advanced development in drug delivery systems that differ from conventional methods. These particles, made from natural or synthetic polymers, are highly acclaimed for their biocompatibility and low toxicity, making them highly suitable for various medical applications.⁷⁴

One of the key features of polymer NPs is their utilization of biodegradable polymers. These materials gradually degrade in the body and are excreted harmlessly, ensuring the safe and effective delivery of drugs. This biodegradable characteristic is crucial as it eliminates any potential adverse effects. Furthermore, these NPs can be custom-tailored to meet specific therapeutic needs.⁷⁵ They can be precisely targeted to specific tissues or organs to reduce adverse interactions with healthy cells by adjusting their size and surface properties, such as charge.

A critical advantage of polymer NPs is their ability to achieve controlled and sustained drug release. This approach ensures prolonged and targeted drug delivery over an extended period, enhancing the efficacy of the treatment and patient compliance with the regimen.⁷⁵ The precision of drug release is particularly vital in cancer therapy, where delivering drugs precisely to tumor cells is crucial for successful treatment outcomes.

Moreover, polymer NPs exhibit outstanding performance in encapsulating various types of drug molecules, including hydrophobic and hydrophilic compounds.^{76,77} This versatility significantly enhances the solubility and stability of drugs that are challenging to administer in other circumstances, addressing a major obstacle in pharmaceutical development. Additionally, these NPs can be modified to carry specific targeting ligands or imaging agents, enhancing their selectivity and allowing real-time tracking of their distribution and effects.

In conclusion, polymer NPs present a highly innovative and efficient method of drug delivery. Their adaptability, safety, and precise targeting capabilities far surpass conventional drug delivery methods. Through ongoing research and development, polymer NPs hold the potential to revolutionize drug therapies across various medical fields, potentially transforming patient care and treatment outcomes.

Nanocrystals

Nanocrystals have emerged as a prominent entity in drug delivery systems, showcasing numerous advantages that set them apart from conventional methods. These systems are uniquely composed of pure drug substances and stabilizers, effectively preventing particle aggregation without the need for carrier materials.⁷⁸ A prominent feature of nanocrystals is their high surface area-to-volume ratio, significantly enhancing the drug's saturation solubility and dissolution rate, serving as an efficient strategy to improve drug solubility, especially for drugs categorized under the Biopharmaceutics Classification System (BCS) II and IV, which commonly face solubility challenges.⁷⁹

An important advantage of nanocrystals is their ability to enhance bioavailability, particularly for oral medications.⁸⁰ The small size and extensive surface area of these nanocrystals aid in more effective drug absorption in the gastrointestinal tract, thus improving overall systemic utilization. In terms of production, nanocrystals demonstrate notable scalability and a straightforward preparation process. They can be efficiently produced through various techniques such as high-pressure homogenization, milling, or precipitation.⁸¹ This simple preparation method and minimal scalability issues position nanocrystals as the preferred candidate for large-scale production, which is crucial in the commercial pharmaceutical manufacturing sector. Furthermore, the potential of nanocrystals includes enhancing drug stability and reducing toxicity. Incorporating stabilizers into the nanocrystal structure can act as a barrier against drug degradation, extending shelf life and improving therapeutic outcomes. The minute size of nanocrystals facilitates tissue penetration, reducing the required dosage to achieve the desired therapeutic effect and consequently lowering the risk of adverse reactions.⁸²

Nanocrystals have demonstrated significant effects in enhancing the bioavailability of a wide range of drugs, with applications in areas such as oncology, cardiovascular diseases, and infectious diseases.^{83–85} Customizable based on size and surface charge, nanocrystals facilitate precise drug delivery to specific tissues or organs, amplifying therapeutic effects.

Nanocrystals, known for their high surface area-to-volume ratio, scalability, ease of preparation, enhanced drug stability, reduced toxicity, and improved bioavailability, show great promise in drug delivery. These characteristics make nanocrystals a valuable alternative to traditional drug delivery systems and an attractive option in drug development. Ongoing research and development are likely to substantially enhance therapeutic efficacy and safety across various medical conditions. Nanomedicine stands out due to its rapid advancements, which can revolutionize drug therapy's efficacy and safety. Compared to traditional drug forms, nanomedicine offers unique advantages such as enhanced biocompatibility, precision, and efficient drug delivery to targeted sites. This reduces dosage requirements and minimizes potential side effects and toxicity.

Nanomedicine

Nanomedicine represents an innovative approach characterized by its ability to be tailored for selective accumulation in diseased tissues, safeguarding healthy cells through surface modifications that enable NPs to recognize and bind to specific cell receptors.⁸⁶ Targeted delivery enhances drug efficacy and reduces the risk of adverse reactions.

One key advantage of nanomedicine over traditional drugs is its reduced side effects and toxicity. By promoting drug release directly at the target site, nanomedicine limits the impact on healthy cells, thereby minimizing adverse effects to the greatest extent possible.^{87,88} This property allows for the administration of higher drug doses, potentially improving treatment outcomes while ensuring patient safety.

Additionally, nanomedicine exhibits stability and can withstand extreme environments such as gastric acid or high shear stresses in the circulation, ensuring drug integrity until reaching the intended target.⁸⁹ Considering the small size of nanomedicine, this stability enhances its ability to penetrate tissues and cells, ensuring optimal drug delivery to the desired site of action.

Nanomedicine is progressively integrating into clinical practice, with the Food and Drug Administration (FDA) approving several nanomedicines, underscoring their significant role in the pharmaceutical industry.^{90,91} This trend foreshadows a promising future for nanomedicine in various medical fields, including cancer therapy, drug delivery, and treatment of central nervous system disorders. Among the primary benefits of nanomedicine is its capacity to address and overcome obstacles in drug development, such as enhancing drug solubility and bioavailability. Moreover, significant reductions in adverse reactions, along with increased drug efficacy and decreased toxicity, are achieved through the notable potential for accumulation and transportation to specific sites. Furthermore, nanomedicine holds the potential to enhance the efficacy of existing drugs, including overcoming drug resistance through targeted mechanisms. They can also improve drug stability, reduce dosing frequency, and hold particular significance for patients with chronic diseases.

Nanomedicine Market Analysis

With advancements in technology and increasing medical demands, the nanomedicine market demonstrates considerable potential and vitality. Nanomedicines offer significant application potential in drug delivery, disease diagnosis, and cancer treatment due to their efficiency, targeted delivery, and reduced side effects, thereby driving market demand.⁹² As nanotechnology continues to advance and clinical trials accumulate, the development and production technologies of nanomedicines are constantly improving, opening new possibilities for treating various diseases and further propelling market growth.⁹³ The aging global population and the increasing number of chronic disease patients are rapidly increasing the demand for innovative drugs and disease management methods. As a crucial direction for future medical advancements, nanomedicine is expected to face more opportunities. Additionally, investments and support from governments and institutions for the biomedical and nanomedicine fields are continuously increasing, undoubtedly boosting the development of the nanomedicine market.⁹⁴


Nanomedicines have been a focal point in clinical trials and patents, with ongoing research and development. They are being actively explored in innovative treatments, cancer therapies, drug delivery systems, and diagnostic imaging.

Some nanomedicines have entered large-scale clinical trials to assess their efficacy, safety, and feasibility, with over 10 drugs approved by the US FDA using lipid nanoparticles (LNPs) for drug delivery to disease sites.⁹⁵ Personalized clinical trials targeting different diseases and subpopulations are also increasing to improve treatment efficacy and reduce side effects.⁹⁶ The number of patents in the nanomedicine field is steadily growing, covering various new drugs, therapeutic methods, and technologies. Interdisciplinary collaborations in patent applications are becoming more common, combining knowledge from biomedical, materials science, and chemistry fields. For example, the team led by Professor Gao Jianqing at Zhejiang University's School of Pharmacy developed self-assembled nanospheres (Nanoassemblies Of a Chlorin e6, L-Ce6 NAs) loaded into dissolvable microneedles, achieving efficient and precise delivery to tumor sites.⁹⁷

Weaknesses: Need for Technical Optimization, Potential Toxicity, and Side Effects

The continuous advancements in nanomedicine development have brought to light numerous advantages, alongside critical challenges and potential drawbacks (Figure 4). Overcoming these obstacles requires a comprehensive and innovative research approach. This effort involves not only enhancing the technology of nanomedicine but also delving


Controlling Particle Size



Potential Side Effects



Potential Side Effects



Potential Toxicity in Humans




Figure 4 Challenges and Weaknesses in Nanomedicine Development. This figure discusses the difficulties in controlling particle size, which is crucial for the effectiveness and safety of nanomedicines. The potential side effects are illustrated, including abdominal pain, vomiting, hair loss, fever, and skin problems. Furthermore, the figure highlights the potential toxicity in humans, emphasizing the importance of thorough biological safety evaluations and monitoring to mitigate these risks.

into their mechanisms of action within the human body and the environment. Through sustained research and development efforts, it is possible to safely and effectively transition nanomedicine from laboratory studies to clinical applications. This process aims to maximize their potential in the medical field, paving the way for the provision of safer and more efficient treatment solutions.

Controlling Particle Size

Controlling particle size in nanomedicine is a crucial aspect that significantly influences the efficacy and toxicity profile of drugs. The particle size of nanomedicines varies widely, typically ranging between 10 and 1000 nm. A key observation in nanomedicine research is that maintaining particle size within a specific range, particularly between 150–200 nm, is beneficial. Particles within this size range do not leak from normal blood vessels but can penetrate through the porous vessels in tumors.⁹⁸ This phenomenon, known as the EPR effect, forms the cornerstone of targeted drug delivery strategies for tumors. However, a significant challenge exists: NPs of this specific size are prone to rapid uptake by the Mononuclear Phagocyte System (MPS), leading to rapid clearance from the bloodstream and reduced accumulation at target sites.⁹⁹

Conversely, for certain drugs such as amphotericin B, nanoscale formulations have been found to increase renal excretion, inadvertently raising the risk of kidney toxicity.¹⁰⁰ Therefore, precise control of NP size is crucial for optimizing therapeutic effects and reducing adverse reactions. Achieving the desired particle size distribution requires careful selection of synthesis methods, considering parameters such as temperature, pressure, and surfactant concentration. Furthermore, particle size influences the stability and drug release kinetics of NPs, emphasizing the necessity for a comprehensive assessment of the size effects on nanomedicine performance.

Despite these challenges, recent advances in nanotechnology have paved the way for new approaches to controlling NP size, shape, and surface characteristics. Microfluidics, ultrasound, and electrospray have proven highly effective in producing uniformly sized, monodisperse NPs with precise size control. Surface modification methods like polyethylene glycol (PEGylation) have shown effectiveness in prolonging the circulation time of NPs in the bloodstream and enhancing their accumulation at target sites.¹⁰¹

In conclusion, careful control of NP size is crucial for the success of nanomedicine, balancing treatment efficacy and toxicity risks. Innovation in NP synthesis and surface engineering plays a key role in overcoming challenges related to size control, ensuring the development of more effective and safer nanomedicine formulations. Continuous research and development in NP size control are essential for advancing the field of nanomedicine delivery and optimizing patient outcomes.

The Potential Toxicity of NPs

The widespread applications of NPs in various fields have underscored their potential toxicity to the human body. The minute size of NPs, while promoting novel interactions with biological surfaces, has raised concerns regarding their ability to induce free radical generation, thereby leading to cellular damage. Furthermore, NPs have been linked to genetic toxicity and mutagenicity.¹⁰² This toxic impact is often exacerbated by the inflammatory responses of macrophages or neutrophils, which produce various reactive oxygen and nitrogen species, leading to oxidative stress.¹⁰³

Without proper control, the accumulation of these free radicals can cause significant harm, potentially resulting in fibrosis, carcinogenesis, and DNA alterations. Additionally, NPs may disrupt mitochondrial membranes, triggering cellular processes such as apoptosis or necrosis.¹⁰⁴ Another significant concern is the systemic distribution following intravenous administration, leading to NP accumulation in vital organs such as the liver, central nervous system, kidneys, and cardiovascular system, potentially eliciting various adverse reactions.¹⁰⁵

Although research assessing the biocompatibility of NPs is ongoing, reaching definitive conclusions regarding their human toxicity remains challenging. Further studies are needed to elucidate the factors influencing NP toxicity and to devise methods to mitigate their adverse effects.

Several factors contribute to the potential toxicity of NPs, including their size, shape, surface charge, and concentration. It has been observed that smaller NPs often exhibit greater toxicity compared to larger ones.¹⁰⁶ Certain shapes, such as nanotubes and nanowires, have been implicated in causing cytotoxicity, inflammation, and fibrosis.^{107,108} Surface

charge is another critical factor, with positively charged NPs generally displaying higher toxicity than negatively charged ones.¹⁰⁹ Additionally, NP concentration plays a crucial role in toxicity, with higher concentrations typically correlating with increased toxic effects.

The toxicological evaluation of NPs involves both *in vitro* and *in vivo* methods. *In vitro* studies employ cultured cells to assess the impact of NPs on cellular function and viability, while *in vivo* research involves the injection of NPs into animal models to understand their toxicity and distribution within the body. These studies play a fundamental role in providing insights into the toxicity of NPs and the factors influencing it.

In summary, the potential toxicity of NPs is a significant focus in the field of nanotechnology. Continuous and innovative research is crucial for unraveling the complexity of NP toxicity, aiming to enhance the safe application of these materials across various domains. Understanding and addressing these challenges are essential for maximizing the potential of NPs in medical and technological advancements.

Potential Side Effects

Nanomedicines are acclaimed as a breakthrough in medical treatment, but they may also bring about a range of potential side effects, similar to traditional medications, necessitating vigilant monitoring and management. These side effects vary widely, from abdominal pain, hair loss, and vomiting to more severe reactions, such as oral mucositis, allergic responses, and various skin issues.¹¹⁰ In certain cases, patients may experience acute allergic reactions, such as fever, hypotension, chest tightness, rash, and muscle pain.^{111,112}

To counteract these adverse reactions, preventive measures may include administering glucocorticoids, antiemetics, antipyretics, and antihistamines prior to giving nanomedicines.¹¹³ Continuous monitoring of patients during and after treatment is crucial to promptly identify and address any newly emerging side effects. Through proactive management, healthcare providers can optimize the safe and effective use of nanomedicines across various medical settings.

In scientific research, particularly in medicine, employing the SWOT analysis framework - traditionally used in business to assess Strengths, Weaknesses, Opportunities, and Threats - is also beneficial. In business, opportunities and threats are typically seen as external factors influencing success or failure. However, in scientific research, it is essential to recognize that these dynamics may also occur internally.

Researchers may encounter internal opportunities, such as new funding sources or groundbreaking discoveries, paving the way for exploring uncharted territories and boosting the development of innovative solutions. These internal factors can significantly impact research outcomes, akin to external influences. Conversely, internal threats like resource constraints, lack of expertise, or inadequate infrastructure may restrict the scope and quality of research.

Therefore, in scientific research, especially in the rapidly evolving field of nanomedicine, conducting a comprehensive SWOT analysis considering internal and external factors is paramount. This approach empowers researchers to leverage their strengths and opportunities while addressing potential threats and weaknesses, thereby paving the way for robust and innovative scientific exploration.

Opportunities: Corporate Revolution Driven by Nanomedicine Technology Optimization

In the era of rapid convergence between medicine and technology, the application of nanotechnology in the field of healthcare has become a noteworthy focus, particularly in the research and application of nanomedicine. These microscopic advancements signify a significant shift in treatment methods and offer unprecedented solutions to global health challenges. From targeted, low-toxicity cancer treatment strategies to therapies capable of penetrating the blood-brain barrier for neurological diseases and innovative mechanisms for antimicrobial treatments, nanomedicine demonstrates its unique potential and advantages across various domains. Concurrently, the swift expansion of the global nanomedicine market is expected to bring forth increased commercial opportunities and research innovation, further propelling progress in the healthcare sector. Against this backdrop, understanding the latest trends, challenges, and opportunities in nanomedicine is crucial for any individual or institution concerned with the future of the medical revolution.

The Nanomedical Revolution

The constantly evolving global market for nanopharmaceuticals presents a lucrative development terrain for pharmaceutical companies, which are expected to witness significant expansion and revenue generation. Predictions indicate a projected compound annual growth rate (CAGR) of 14.0% from 2017 to 2022, with the market value expected to reach \$293.1 billion by 2022. The field of nanomedicine is anticipated to sustain steady growth.¹¹⁴ This expansion signifies a commercial opportunity and heralds the potential for nanopharmaceuticals to substantially reduce healthcare costs by enhancing treatment efficiency and effectiveness, consequently improving patient outcomes while decreasing overall medical expenses.

The escalating demand for nanopharmaceuticals is propelled by several key driving factors, including the increasing prevalence of chronic diseases, the growing need for personalized medicine, and the emergence of innovative nanotechnology-driven drug delivery systems. The ongoing development of novel and groundbreaking nanopharmaceuticals is expected to further propel market growth. By 2019, nanopharmaceuticals are projected to constitute 22% of the entire pharmaceutical market, underscoring their escalating significance in the pharmaceutical industry.

Moreover, the expansion of the global nanopharmaceutical market has paved the way for collaboration across academic, industry, and governmental sectors. This collaborative environment is likely to boost research and development in the field of nanopharmaceuticals, potentially leading to the emergence of numerous novel treatment approaches for various diseases.

The continuously expanding global market for nanopharmaceuticals offers significant opportunities for pharmaceutical enterprises and healthcare providers to deliver more efficient and effective patient care while optimizing medical costs. This market growth also fosters interdisciplinary cooperation, which is crucial for driving research and innovation in the field, thus paving the way for groundbreaking therapeutic solutions for various health conditions. With the sustained expansion of the nanopharmaceutical market, its impact on the pharmaceutical industry and healthcare services is expected to be profound and far-reaching.

Nanomedicine

Nanomedicine is at the forefront of global research and development, as highlighted by the increasing number of nanomedicines approved by the FDA in the United States for commercial use, totaling around 100. The FDA and other regulatory bodies, such as the European Medicines Agency (EMA), have also recognized the potential of nanomedicine. EMA has approved 11 nanomedicines, including 8 first-generation formulations like liposomes, showcasing Europe's progressive stance on nanomedicine. Additionally, ongoing clinical trials of 48 nanomedicines within the European Union underscore the interest and commitment to exploring the benefits of nanomedicines.¹¹⁵

Nanomedicines offer several key advantages over traditional drugs, including enhanced bioavailability, improved solubility, and reduced toxicity. They can target specific areas of the body, making them more effective than conventional medications.

The global nanotechnology sector has seen the emergence of nearly 200 clusters, with Europe holding a significant position with 80 clusters, while Asia and North America have 50 clusters each, and other regions account for 20.¹¹⁶ These clusters serve as interdisciplinary melting pots, fostering collaborations and deepening our understanding of NPs and their interactions with biological systems. These collaborative efforts facilitate the transfer of knowledge and technology from academia to industry, ultimately leading to the development of innovative nanomedicines with superior therapeutic efficacy and minimal side effects.

The growth of the nanomedicine market is not limited to the United States and Europe but also sees a significant rise in demand in the Asia-Pacific region. According to a research report on the Asia-Pacific nanomedicine market, this market is projected to grow at a compound annual growth rate of 16.3% from 2019 to 2024, reaching a market value of \$482.4 billion by 2024.¹¹⁷ This growth trend is primarily driven by the surge in demand for effective treatment of chronic diseases such as cancer and diabetes and increased investments by pharmaceutical companies in nanomedicine research and development.

In conclusion, the global nanomedicine sector is experiencing dynamic and extensive growth, driven by regulatory approvals, clinical trials, and interdisciplinary collaborations. The sharp rise in demand across regions, combined with the

unique advantages of nanomedicine, foretells a promising future for this innovative field. As research progresses, the potential of nanomedicines to revolutionize medical treatments and outcomes becomes increasingly tangible.

Nanotechnology

Research based on Nanotechnology is expanding the potential therapeutic possibilities far beyond the realm of cancer treatment. Although nanodrugs currently hold about 35% of the nanomedicine market, the exploration of nanodrugs in other crucial clinical areas is thriving. Particularly noteworthy is the progress in the field of neurology, where nanomedicine is advancing the development of drug delivery systems capable of crossing the blood-brain barrier. This advancement brings significant hope for treating neurodegenerative diseases such as Alzheimer's and Parkinson's, which have been greatly hindered by the effective delivery of drugs to the brain.¹¹⁸

In the battle against infections, nanomedicine is increasingly becoming a key player. With traditional antibiotics facing challenges like significant side effects and increasing bacterial resistance, nanodrugs are receiving attention for their ability to deliver drugs specifically to infected tissues.¹¹⁹ This targeted approach may reduce side effects and potentially enhance treatment efficacy. Furthermore, the exploration of nanodrugs for treating viral and fungal infections is also underway, expanding the spectrum of infectious diseases that can be addressed using this technology.

The impact of nanotechnology extends to vaccine development and diagnostic imaging. NPs have been proven effective vaccine carriers, offering a promising strategy for combating infectious diseases. In the field of medical imaging, NPs are used as contrast agents, enhancing the precision of disease diagnosis.^{120,121}

The potential applications of nanodrugs span a wide range of medical fields, including but not limited to cardiovascular, endocrine, bone-related, hematology, immunology, liver, skin, and ophthalmic diseases.^{122–130} With the advancement of nanotechnology and drug delivery systems research, nanodrugs are poised to become the preferred treatment option for a wide array of health conditions.

Considering the expected rapid expansion of the global nanodrug market, the ongoing increase in research and development in the field of nanomedicine is likely to continue. This influx of resources will undoubtedly drive further advancements in the field and potentially revolutionize treatment methods across various medical disciplines. The future of nanomedicine, with its expanding horizons and innovative potential, is set to redefine treatment strategies and patient care on a global scale.

Threats: Critical Challenges in the Development of Nanomedicine Technology

The advancement of nanotechnology is paving the way for new frontiers in medical research and treatment. Nanomedicine, as a critical component of this progress, holds the promise of bringing revolutionary changes to the treatment of various diseases. Nanodrugs, leveraging their unique size and physicochemical properties, offer unprecedented therapeutic possibilities, thereby enhancing the efficacy and safety of medications. However, the rapid development in this emerging field also presents a range of unprecedented challenges and opportunities.

On the one hand, the potential of nanomedicine is virtually limitless, capable of providing innovative solutions for previously untreatable diseases, including but not limited to targeted drug delivery, vaccine development, and medical imaging. Their ability to traverse the blood-brain barrier, improve drug bioavailability, and reduce side effects brings new hope to patients.

On the other hand, as these technologies advance, the inadequacy of regulatory frameworks and high research and development costs have become significant obstacles that cannot be ignored. To some extent, the lack of specialized regulatory guidance and standardized testing protocols for nanodrugs and the high costs from the laboratory to market hinder the further development and application of nanomedicine.

This review presents the primary challenges facing nanomedicine, including regulatory barriers, R&D and production cost issues, and the implications of these challenges for the future of nanodrugs. Additionally, it explores potential approaches to overcoming these challenges, highlighting the importance of interdisciplinary collaboration and innovative strategies. Based on these approaches, we aim to drive the continual advancement of nanomedicine, ultimately bringing positive impacts to global health.

Regulatory Barriers

The rapid development of nanomedicine has revealed a myriad of opportunities and challenges. The application of nanotechnology in drug development and disease treatment has revolutionized the pharmaceutical field; however, it has also introduced regulatory hurdles, particularly concerning safety protocols. A key challenge is the lack of specific regulatory guidance for the development and clinical application of nanodrugs.¹³¹ This ambiguity has created a complex environment where researchers and developers must navigate through this unknown regulatory territory to ensure their products meet the necessary standards.

Evaluating nanodrugs within the traditional framework designed for standard drugs presents a unique dilemma. Their complex multi-component characteristics require a more intricate evaluation, considering the unique properties of these drugs. NPs possess specific attributes such as size, shape, surface area, and reactivity, all of which may impact their pharmacokinetics, biodistribution, and potential toxicity. Developing new analytical tools and standardizing evaluation protocols for nanodrugs is a crucial step in characterizing the physical and chemical properties of NPs.¹³²

The lack of a standardized regulatory framework for nanodrugs also brings uncertainty to investors and pharmaceutical companies. Hesitation in investing in nanomedicine stems from these potential risks and the unclear regulatory environment. Establishing clear regulatory guidelines is essential to ensure the safety and efficacy of nanodrugs, thereby driving investments and innovation in this burgeoning field.

Addressing the regulatory challenges of nanodrugs is paramount. Conducting comprehensive assessments of each component of these drugs while ensuring safety and reducing toxicity is a resource-intensive process, which may delay the market entry of new nanodrugs.¹³¹ Production and quality control of nanodrugs also face significant obstacles, necessitating precise control of their physical and chemical attributes.

Regulatory bodies, academic institutions, and industry stakeholders must collaborate to overcome these challenges. This collaboration should aim to establish standardized processes for evaluating and approving nanodrugs. Developing clear guidelines on characteristics, assessment, and quality control is crucial and requires the introduction of new analytical tools and technologies. These developments can enhance assessment efficiency and accuracy, thus achieving a smoother and more reliable nanodrug approval process.

In addition to establishing standardized procedures, creating a post-market surveillance framework for nanodrugs is crucial. Continuous monitoring of these drugs in the market is essential to promptly identify and address any adverse effects.

In conclusion, by concerted efforts and the formulation of comprehensive procedures and monitoring systems, the regulatory barriers associated with nanodrugs can be effectively addressed. Confronting these challenges will expedite the progress of safe and efficient nanodrugs, significantly impacting the treatment of various diseases.

Research and Production Costs in Nanomedicine

The development and production of nanomedicines are characterized by high costs, posing significant challenges to their widespread application. The process of translating new molecules into drug formulations, including nanomedicines, is inherently complex and requires substantial funding.¹³³ The costs during the clinical trial phase alone can range from 101.2 billion to 174.4 billion.¹³⁴ Furthermore, the intricate nature of nanomedicines leads to a cost increase of approximately 15% compared to traditional drugs.¹³⁵

To alleviate these financial barriers, some researchers advocate for directly developing nanoscale active drugs, which may be more cost-effective than creating nanoscale versions of existing drugs. However, the high failure rates associated with innovative nanotechnological products result in cost escalation, posing significant financial risks for smaller research institutions and companies.

Enhancing the accessibility and affordability of nanomedicines while reducing development costs while maintaining their quality and safety is crucial. One approach involves simplifying the manufacturing process to lower costs. Collaborative efforts between academic institutions and industry are also vital, enabling the sharing of resources, knowledge, and expertise. This collaborative model can reduce redundant efforts and accelerate the drug development timeline. Additionally, regulatory agencies can reduce costs by establishing clear standard guidelines, thereby decreasing the time and resources required for regulatory compliance.

Investing in innovative technologies and methods can further alleviate the financial burden of developing nanomedicines. For example, artificial intelligence and machine learning algorithms can significantly expedite the identification of promising drug candidates, reducing the scope of preclinical and clinical trials. Artificial intelligence can also enhance drug delivery and formulation processes, leading to more efficient and targeted therapies. Furthermore, adopting advanced manufacturing technologies, such as continuous manufacturing processes, can increase production efficiency and reduce waste.

In this domain, collaboration among stakeholders is paramount. Concerted efforts from academia, industry, and regulatory bodies can streamline the drug development process, making it simpler, more cost-effective, and expanding avenues for patients to access new treatment options. This collaboration can drive the development of new technologies, streamline the drug development process, enhance safety and efficacy, and discover new sources of funding, such as public-private partnerships. Through cooperative partnerships, these entities can overcome the inherent financial and logistical challenges in drug development and manufacturing, paving the way for safer, more effective, and more affordable treatment options for patients.

These attributes provide essential insights for a SWOT analysis, highlighting the distinct advantages of nanomedicines over traditional drugs. Nevertheless, as with any emerging field, there are challenges and obstacles to overcome, such as regulatory hurdles and high development costs. Addressing these issues is critical to further advancement and success in this field. By recognizing and tackling these challenges, we can continue to harness the benefits of nanomedicines and develop innovative solutions to their limitations. Ultimately, the success of nanomedicine will hinge on our ability to effectively overcome these challenges and fully realize its potential in enhancing human health.

Conclusion

Nanomedicine stands at the forefront of medical innovation, showcasing the powerful convergence of nanotechnology and medical science. This interdisciplinary field utilizes the ability to manipulate and control materials at the nanoscale level through nanotechnology, thus advancing the development of highly targeted and efficient drug delivery systems. The continuously growing nanomedicine market reflects the increasing demand for effective and safe treatments for various diseases such as cancer, cardiovascular, and neurological disorders. Apart from drug delivery, the versatility of nanomedicine is also evident in areas such as diagnostic imaging, biomaterials, and tissue engineering.

As nanomedicine technologies continue to evolve, they are poised to play a crucial role in personalized therapy, tissue engineering, and drug delivery systems. These advancements will enable more effective customized treatment plans for patients, improve outcomes in organ transplantation and repair, and enhance drug absorption while reducing dosages and toxicity.^{136,137}

However, nanomedicine also faces significant challenges and threats, including production standardization, biosafety, and regulatory oversight. Achieving consistent quality in large-scale production is difficult, which can impact the quality and efficacy of drugs. Ensuring the safety of nanomedicine products and the lack of a unified regulatory framework can lead to either insufficient or excessive regulation, affecting progress and market access.¹³⁸

To address these challenges, it is crucial to implement standardized production processes, robust biosafety evaluations, and comprehensive regulatory frameworks. Establishing strict production protocols, monitoring standards, and quality controls will ensure product consistency and quality. Additionally, biological safety assessments of nanomedicine products must be enhanced through continuous monitoring of potential risks and proactive solution-seeking. Furthermore, the establishment of a complete regulatory framework and promotion of international cooperation are imperative to ensure compliance and uphold scientific integrity in market access. These strategies will significantly influence the development and application of nanomedicine.¹³⁹

The revolutionary potential of nanomedicine lies in its ability to transform disease prevention, diagnosis, and treatment. Strategies based on nanotechnology provide enhanced specificity, reduce side effects and toxicity, while improving patient prognosis. For instance, NPs have the ability to cross biological barriers and selectively target malignant tumors, demonstrating a paradigm shift in cancer treatment focusing on directly intervening in tumors while preserving healthy tissues.

SWOT analysis of nano-drugs




Figure 5 SWOT Analysis of Nanomedicine. The strengths include better biocompatibility, improved targeting, reduced side effects and toxicity, and higher stability. Weaknesses are identified, such as the need to explore appropriate particle sizes and the incomplete understanding of toxic and side effects on the human body. Opportunities are noted in the continued market growth, global recognition, and wide range of applications for nano-drugs. The threats include the lack of clear standards in the supervision mechanism and the high costs associated with research and development, as well as manufacturing.

Ongoing research and development in the field of nanomedicine hold the promise of addressing some of the most critical medical challenges and significantly improving global health. A comprehensive SWOT analysis reveals the strong position of nanomedicine in clinical applications and its immense potential in medical interventions. One such promising area is regenerative therapy, particularly in organ transplantation, where nanotechnology can significantly enhance organ engineering capabilities.^{140,141} Furthermore, the integration of nanotechnology with 3D printing has opened new avenues in healthcare, enabling the production of customized medical devices and implants with superior performance and biocompatibility.¹⁴² For instance, the development of 3D-printed spinal implants embedded with NPs to promote bone growth is a clear example of this synergy, demonstrating encouraging results in both preclinical and clinical trials.¹⁴³

A SWOT analysis of the clinical applications of nanomedicine provides a strategic roadmap, guiding researchers to leverage strengths and opportunities while addressing challenges and threats (Figure 5). Advancing nanomedicine requires interdisciplinary approaches and collaboration among researchers, clinicians, and regulatory agencies. By uniting these diverse expertise, we can accelerate the development of safe and effective nanomedicines, paving the way for groundbreaking medical treatments that significantly enhance human health and well-being.

Data Sharing Statement

All data can be provided as needed.

Funding

Thanks for the financial support by the Natural Science Foundation for Young Scholars of Sichuan Province (No. 2022NSFSC1587), Nanchong science and technology plan project (No. 23JCYJPT0062), Doctoral research Foundation of North Sichuan Medical College (No. CBY22-QDA14).

Disclosure

The authors declare no conflict of interest.

References

1. Li K, Lin M, Huang K, et al. Therapeutic effect and mechanism of action of pterostilbene nano drugs in dry eye models. *Exp Eye Res.* 2024;241:109836. doi:10.1016/j.exer.2024.109836
2. Wang Z, Tong Q, Li T, Qian Y. Nano drugs delivery system: a novel promise for the treatment of atrial fibrillation. *Front Cardiovasc Med.* 2022;9:906350. doi:10.3389/fcvm.2022.906350
3. Zhou X, Smith QR, Liu X. Brain penetrating peptides and peptide-drug conjugates to overcome the blood-brain barrier and target CNS diseases. *Wiley Interdiscip Rev Nanomed Nanobiotechnol.* 2021;13(4):e1695. doi:10.1002/wnan.1695
4. Ji B, Wei M, Yang B. Recent advances in nanomedicines for photodynamic therapy (PDT)-driven cancer immunotherapy. *Theranostics.* 2022;12(1):434–458. doi:10.7150/thno.67300
5. Cheng Z, Li M, Dey R, Chen Y. Nanomaterials for cancer therapy: current progress and perspectives. *J Hematol Oncol.* 2021;14(1):85. doi:10.1186/s13045-021-01096-0
6. Han H, Li S, Zhong Y, et al. Emerging pro-drug and nano-drug strategies for gemcitabine-based cancer therapy. *Asian J Pharm Sci.* 2022;17(1):35–52. doi:10.1016/j.ajps.2021.06.001
7. Ramos TI, Villacis-Aguirre CA, López-Aguilar KV, et al. The hitchhiker's guide to human therapeutic nanoparticle development. *Pharmaceutics.* 2022;14(2):247. doi:10.3390/pharmaceutics14020247
8. Jat S, Bhatt M, Roychowdhury S, et al. Preparation and characterization of amoxapine- and naringin-loaded solid lipid nanoparticles: drug-release and molecular-docking studies. *Nanomedicine.* 2022;17(28):2133–2144. doi:10.2217/nnm-2022-0167
9. Fang R, Liao Y, Qiu H, Liu Y, Lin S, Chen H. Chitosan oligosaccharide modified bovine serum albumin nanoparticles for improving oral bioavailability of naringenin. *Curr Drug Deliv.* 2024;21(8):1142–1150. doi:10.2174/1567201820666230718143726
10. De Jong WH, Borm PJ. Drug delivery and nanoparticles: applications and hazards. *Int J Nanomed.* 2008;3(2):133–149. doi:10.2147/ijn.s596
11. Rizvi SAA, Saleh AM. Applications of nanoparticle systems in drug delivery technology. *Saudi Pharm J.* 2018;26(1):64–70. doi:10.1016/j.jsps.2017.10.012
12. Fang J, Nakamura H, Maeda H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. *Adv Drug Deliv Rev.* 2011;63(3):136–151. doi:10.1016/j.addr.2010.04.009
13. Zhong G, Long H, Zhou T, et al. Blood-brain barrier Permeable nanoparticles for Alzheimer's disease treatment by selective mitophagy of microglia. *Biomaterials.* 2022;288:121690. doi:10.1016/j.biomaterials.2022.121690
14. Patra JK, Das G, Fraceto LF, et al. Nano based drug delivery systems: recent developments and future prospects. *J Nanobiotechnology.* 2018;16(1):71. doi:10.1186/s12951-018-0392-8
15. Laurindo LF, de Carvalho GM, de Oliveira Zanuso B, et al. Curcumin-based nanomedicines in the treatment of inflammatory and immunomodulated diseases: an evidence-based comprehensive review. *Pharmaceutics.* 2023;15(1):229. doi:10.3390/pharmaceutics15010229
16. Tenchov R, Bird R, Curtze AE, Zhou Q. Lipid nanoparticles—from liposomes to mRNA vaccine delivery, a landscape of research diversity and advancement. *ACS Nano.* 2021;15(11):16982–17015. doi:10.1021/acsnano.1c04996
17. Hong L, Li W, Li Y, Yin S. Nanoparticle-based drug delivery systems targeting cancer cell surfaces. *RSC Adv.* 2023;13(31):21365–21382. doi:10.1039/d3ra02969g
18. Bilardo R, Traldi F, Vdovchenko A, Resmini M. Influence of surface chemistry and morphology of nanoparticles on protein Corona formation. *Wiley Interdiscip Rev Nanomed Nanobiotechnol.* 2022;14(4):e1788. doi:10.1002/wnan.1788
19. Ramachandran S, Satapathy SR, Dutta T. Delivery Strategies for mRNA Vaccines. *Pharmaceut Med.* 2022;36(1):11–20. doi:10.1007/s40290-021-00417-5
20. Liu T, Gao C, Gu D, Tang H. Cell-based carrier for targeted hitchhiking delivery. *Drug Deliv Transl Res.* 2022;12(11):2634–2648. doi:10.1007/s13346-022-01149-y
21. Ding R, Padilla Espinosa IM, Loevlie D, et al. Size-dependent shape distributions of platinum nanoparticles. *Nanoscale Adv.* 2022;4(18):3978–3986. doi:10.1039/d2na00326k
22. Varma S, Dey S, Palanisamy D. Cellular uptake pathways of nanoparticles: process of endocytosis and factors affecting their fate. *Curr Pharm Biotechnol.* 2022;23(5):679–706. doi:10.2174/1389201022666210714145356
23. Santacruz-Márquez R, González-De Los Santos M, Hernández-Ochoa I. Ovarian toxicity of nanoparticles. *Reprod Toxicol.* 2021;103:79–95. doi:10.1016/j.reprotox.2021.06.002
24. Raval J, Gongadze E, Benčina M, et al. Mechanical and electrical interaction of biological membranes with nanoparticles and nanostructured surfaces. *Membranes.* 2021;11(7):533. doi:10.3390/membranes11070533
25. Sun Q, Zhu Y, Du J. Recent progress on charge-reversal polymeric nanocarriers for cancer treatments. *Biomed Mater.* 2021;16(4):10.1088/1748-605X/abfb5. doi:10.1088/1748-605X/abfb5
26. Witika BA, Choonara YE, Demana PH. A SWOT analysis of nano co-crystals in drug delivery: present outlook and future perspectives. *RSC Adv.* 2023;13(11):7339–7351. doi:10.1039/d3ra00161j
27. Smith JD, Hasan M. Quantitative approaches for the evaluation of implementation research studies. *Psychiatry Res.* 2020;283:112521. doi:10.1016/j.psychres.2019.112521
28. Waltz TJ, Powell BJ, Fernández ME, Abadie B, Damschroder LJ. Choosing implementation strategies to address contextual barriers: diversity in recommendations and future directions. *Implement Sci.* 2019;14(1):42. doi:10.1186/s13012-019-0892-4
29. Damschroder LJ. Clarity out of chaos: use of theory in implementation research. *Psychiatry Res.* 2020;283:112461. doi:10.1016/j.psychres.2019.06.036
30. Camacho J, Zanoletti-Mannello M, Landis-Lewis Z, Kane-Gill SL, Boyce RD. A conceptual framework to study the implementation of clinical decision support Systems (BEAR): literature review and concept mapping. *J Med Internet Res.* 2020;22(8):e18388. doi:10.2196/18388

31. Agarwal A, Majzoub A, Baskaran S, et al. Sperm DNA fragmentation: a new guideline for clinicians. *World J Mens Health*. 2020;38(4):412–471. doi:10.5534/wjmh.200128
32. Überall M, Werner-Felmayer G. Integrative biology and big-data-centrism: mapping out a bioscience ethics perspective with a S.W.O.T. matrix. *OMICS*. 2019;23(8):371–379. doi:10.1089/omi.2019.0043
33. Salvador M, Moyano A, Martínez-García JC, Blanco-López MC, Rivas M. Synthesis of superparamagnetic iron oxide nanoparticles: SWOT analysis towards their conjugation to biomolecules for molecular recognition applications. *J Nanosci Nanotechnol*. 2019;19(8):4839–4856. doi:10.1166/jnn.2019.16931
34. Li ZZ, Lin H, Xu YM, et al. Application of PRI-E-a combined learning method in oral and maxillofacial oncology education. *Sci Rep*. 2024;14(1):8127. doi:10.1038/s41598-024-58878-y
35. Pandey PC. Properties, applications and toxicities of organotrialkoxysilane-derived functional metal nanoparticles and their multimetallic analogues. *Materials (Basel)*. 2023;16(5):2052. doi:10.3390/ma16052052
36. Maiti D, Tong X, Mou X, Yang K. Carbon-based nanomaterials for biomedical applications: a recent study. *Front Pharmacol*. 2019;9:1401. doi:10.3389/fphar.2018.01401
37. Gadeval A, Maheshwari R, Raval N, Kalyane D, Kalia K, Tekade RK. Green graphene nanoplates for combined photo-chemo-thermal therapy of triple-negative breast cancer. *Nanomedicine*. 2020;15(6):581–601. doi:10.2217/nmm-2019-0380
38. Saghatchi F, Mohseni-Dargah M, Akbari-Birgani S, Saghatchi S, Kaboudin B. Cancer therapy and imaging through functionalized carbon nanotubes decorated with magnetite and gold nanoparticles as a multimodal tool. *Appl Biochem Biotechnol*. 2020;191(3):1280–1293. doi:10.1007/s12010-020-03280-3
39. Ferrier DC, Honeychurch KC. Carbon Nanotube (CNT)-based biosensors. *Biosensors*. 2021;11(12):486. doi:10.3390/bios11120486
40. Acntf C, Pereira PR, Paschoalin VMF. Preparation and characterization of nanoliposomes for the entrapment of bioactive hydrophilic globular proteins. *J Vis Exp*. 2019;2019:150. doi:10.3791/59900
41. Akbarzadeh A, Rezaei-Sadabady R, Davaran S, et al. Liposome: classification, preparation, and applications. *Nanoscale Res Lett*. 2013;8(1):102. doi:10.1186/1556-276X-8-102
42. Kurmi BD, Kayat J, Gajbhiye V, Tekade RK, Jain NK. Micro- and nanocarrier-mediated lung targeting. *Expert Opin Drug Deliv*. 2010;7(7):781–794. doi:10.1517/17425247.2010.492212
43. Di J, Gao X, Du Y, Zhang H, Gao J, Zheng A. Size, shape, charge and “stealthy” surface: carrier properties affect the drug circulation time in vivo. *Asian J Pharm Sci*. 2021;16(4):444–458. doi:10.1016/j.ajps.2020.07.005
44. Maheshwari R, Raval N, Tekade RK. Surface modification of biomedically essential nanoparticles employing polymer coating. *Methods Mol Biol*. 2019;2000:191–201. doi:10.1007/978-1-4939-9516-5_13
45. Kumawat A, Dapse P, Kumar N, et al. Budding Alliance of Nanotechnology in RNA Interference Therapeutics. *Curr Pharm Des*. 2018;24(23):2632–2643. doi:10.2174/1381612824666180807113948
46. Agreles MAA, Cavalcanti IDL, Cavalcanti IMF. Synergism between metallic nanoparticles and antibiotics. *Appl Microbiol Biotechnol*. 2022;106(11):3973–3984. doi:10.1007/s00253-022-12001-1
47. Işıklan N, Polat S. Synthesis and characterization of thermo/pH-sensitive pectin-graft-poly(dimethylaminoethyl methacrylate) coated magnetic nanoparticles. *Int J Biol Macromol*. 2020;164:4499–4515. doi:10.1016/j.ijbiomac.2020.09.002
48. Zhao Z, Li M, Zeng J, et al. Recent advances in engineering iron oxide nanoparticles for effective magnetic resonance imaging. *Bioact Mater*. 2021;12:214–245. doi:10.1016/j.bioactmat.2021.10.014
49. Zhang J, Mou L, Jiang X. Surface chemistry of gold nanoparticles for health-related applications. *Chem Sci*. 2020;11(4):923–936. doi:10.1039/c9sc06497d
50. Akgönüllü S, Yavuz H, Denizli A. SPR nanosensor based on molecularly imprinted polymer film with gold nanoparticles for sensitive detection of aflatoxin B1. *Talanta*. 2020;219:121219. doi:10.1016/j.talanta.2020.121219
51. Yang Y, Yu Y, Chen H, et al. Illuminating platinum transportation while maximizing therapeutic efficacy by gold nanoclusters via simultaneous near-infrared-I/II imaging and glutathione scavenging. *ACS Nano*. 2020;14(10):13536–13547. doi:10.1021/acsnano.0c05541
52. Fouda MMG, Dosoky WM, Radwan NS, Abdelsalam NR, Taha AE, Khafaga AF. Oral administration of silver nanoparticles-adorned starch as a growth promoter in poultry: immunological and histopathological study. *Int J Biol Macromol*. 2021;187:830–839. doi:10.1016/j.ijbiomac.2021.07.157
53. Yin IX, Zhang J, Zhao IS, Mei ML, Li Q, Chu CH. The antibacterial mechanism of silver nanoparticles and its application in dentistry. *Int J Nanomed*. 2020;15:2555–2562. doi:10.2147/IJN.S246764
54. Lee SH, Jun BH. Silver nanoparticles: synthesis and application for nanomedicine. *Int J Mol Sci*. 2019;20(4):865. doi:10.3390/ijms20040865
55. Akbarzadeh A, Khalilov R, Mostafavi E, et al. Role of dendrimers in advanced drug delivery and biomedical applications: a review. *Exp Oncol*. 2018;40(3):178–183. doi:10.31768/2312-8852.2018.40
56. Mansuri S, Kesharwani P, Tekade RK, Jain NK. Lyophilized mucoadhesive-dendrimer enclosed matrix tablet for extended oral delivery of albendazole. *Eur J Pharm Biopharm*. 2016;102:202–213. doi:10.1016/j.ejpb.2015.10.015
57. Kesharwani P, Tekade RK, Jain NK. Generation dependent cancer targeting potential of poly(propyleneimine) dendrimer. *Biomaterials*. 2014;35(21):5539–5548. doi:10.1016/j.biomaterials.2014.03.064
58. Tekade RK, Dutta T, Gajbhiye V, Jain NK. Exploring dendrimer towards dual drug delivery: pH responsive simultaneous drug-release kinetics. *J Microencapsul*. 2009;26(4):287–296. doi:10.1080/02652040802312572
59. Yousefi M, Narmani A, Jafari SM. Dendrimers as efficient nanocarriers for the protection and delivery of bioactive phytochemicals. *Adv Colloid Interface Sci*. 2020;278:102125. doi:10.1016/j.cis.2020.102125
60. Abbasi E, Aval SF, Akbarzadeh A, et al. Dendrimers: synthesis, applications, and properties. *Nanoscale Res Lett*. 2014;9(1):247. doi:10.1186/1556-276X-9-247
61. Raval N, Maheshwari R, Kalia K, Tekade RK. Fabrication of mucoadhesive-dendrimers as solid dosage forms. *Methods Mol Biol*. 2019;2000:93–109. doi:10.1007/978-1-4939-9516-5_9
62. Dwivedi N, Shah J, Mishra V, et al. Dendrimer-mediated approaches for the treatment of brain tumor. *J Biomater Sci Polym Ed*. 2016;27(7):557–580. doi:10.1080/09205063.2015.1133155

63. Gorzkiewicz M, Konopka M, Janaszewska A, et al. Application of new lysine-based peptide dendrimers D3K2 and D3G2 for gene delivery: specific cytotoxicity to cancer cells and transfection in vitro. *Bioorg Chem.* 2020;95:103504. doi:10.1016/j.bioorg.2019.103504
64. Zhang S, Lloveras V, Pulido D, et al. Radical dendrimers based on biocompatible oligoethylene glycol dendrimers as contrast agents for MRI. *Pharmaceutics.* 2020;12(8):772. doi:10.3390/pharmaceutics12080772
65. Ghezzi M, Pescina S, Padula C, et al. Polymeric micelles in drug delivery: an insight of the techniques for their characterization and assessment in biorelevant conditions. *J Control Release.* 2021;332:312–336. doi:10.1016/j.jconrel.2021.02.031
66. Jhaveri AM, Torchilin VP. Multifunctional polymeric micelles for delivery of drugs and siRNA. *Front Pharmacol.* 2014;5:77. doi:10.3389/fphar.2014.00077
67. Wickens JM, Alsaab HO, Kesharwani P, et al. Recent advances in hyaluronic acid-decorated nanocarriers for targeted cancer therapy. *Drug Discov Today.* 2017;22(4):665–680. doi:10.1016/j.drudis.2016.12.009
68. Kesharwani P, Gajbhiye V, Tekade RK, Jain NK. Evaluation of dendrimer safety and efficacy through cell line studies. *Curr Drug Targets.* 2011;12(10):1478–1497. doi:10.2174/138945011796818135
69. Choudhury H, Maheshwari R, Pandey M, Tekade M, Gorain B, Tekade RK. Advanced nanoscale carrier-based approaches to overcome biopharmaceutical issues associated with anticancer drug ‘Etoposide’. *Mater Sci Eng C Mater Biol Appl.* 2020;106:110275. doi:10.1016/j.msec.2019.110275
70. Choudhury H, Gorain B, Pandey M, et al. Recent advances in TPGS-based nanoparticles of docetaxel for improved chemotherapy. *Int J Pharm.* 2017;529(1–2):506–522. doi:10.1016/j.ijpharm.2017.07.018
71. Xu J, Yan X, Ge X, et al. Novel multi-stimuli responsive functionalized PEG-based co-delivery nanovehicles toward sustainable treatments of multidrug resistant tumor. *J Mater Chem B.* 2021;9(5):1297–1314. doi:10.1039/d0tb02192j
72. Lalu L, Tambe V, Pradhan D, et al. Novel nanosystems for the treatment of ocular inflammation: current paradigms and future research directions. *J Control Release.* 2017;268:19–39. doi:10.1016/j.jconrel.2017.07.035
73. Banik BL, Fattahi P, Brown JL. Polymeric nanoparticles: the future of nanomedicine. *Wiley Interdiscip Rev Nanomed Nanobiotechnol.* 2016;8(2):271–299. doi:10.1002/wnan.1364
74. El Yousfi R, Brahmi M, Dalli M, et al. Recent advances in nanoparticle development for drug delivery: a comprehensive review of polycaprolactone-based multi-arm architectures. *Polymers.* 2023;15(8):1835. doi:10.3390/polym15081835
75. Zielińska A, Carreiró F, Oliveira AM, et al. Polymeric nanoparticles: production, characterization, toxicology and ecotoxicology. *Molecules.* 2020;25(16):3731. doi:10.3390/molecules25163731
76. Su Y, Zhang B, Sun R, et al. PLGA-based biodegradable microspheres in drug delivery: recent advances in research and application. *Drug Deliv.* 2021;28(1):1397–1418. doi:10.1080/10717544.2021.1938756
77. Jiang Q, Liu Y, Guo R, et al. Erythrocyte-cancer hybrid membrane-camouflaged melanin nanoparticles for enhancing photothermal therapy efficacy in tumors. *Biomaterials.* 2019;192:292–308. doi:10.1016/j.biomaterials.2018.11.021
78. Jungghans JU, Müller RH. Nanocrystal technology, drug delivery and clinical applications. *Int J Nanomed.* 2008;3(3):295–309. doi:10.2147/ijn.s595
79. Wang M, Rutledge GC, Myerson AS, Trout BL. Production and characterization of carbamazepine nanocrystals by electrospraying for continuous pharmaceutical manufacturing. *J Pharm Sci.* 2012;101(3):1178–1188. doi:10.1002/jps.23024
80. Gigliobianco MR, Casadidio C, Censi R, Di Martino P. Nanocrystals of poorly soluble drugs: drug bioavailability and physicochemical stability. *Pharmaceutics.* 2018;10(3):134. doi:10.3390/pharmaceutics10030134
81. Chen XQ, Pang GX, Shen WH, Tong X, Jia MY. Preparation and characterization of the ribbon-like cellulose nanocrystals by the cellulase enzymolysis of cotton pulp fibers. *Carbohydr Polym.* 2019;207:713–719. doi:10.1016/j.carbpol.2018.12.042
82. Lu Y, Lv Y, Li T. Hybrid drug nanocrystals. *Adv Drug Deliv Rev.* 2019;143:115–133. doi:10.1016/j.addr.2019.06.006
83. Sharma M, Mehta I. Surface stabilized atorvastatin nanocrystals with improved bioavailability, safety and antihyperlipidemic potential. *Sci Rep.* 2019;9(1):16105. doi:10.1038/s41598-019-52645-0
84. Luo M, Sun H, Jiang Q, et al. Novel nanocrystal injection of insoluble drug anlotinib and its antitumor effects on hepatocellular carcinoma. *Front Oncol.* 2021;11:777356. doi:10.3389/fonc.2021.777356
85. Imtiaz Y, Tuga B, Smith CW, et al. Synthesis and cytotoxicity studies of wood-based cationic cellulose nanocrystals as potential immunomodulators. *Nanomaterials.* 2020;10(8):1603. doi:10.3390/nano10081603
86. Sebak AA, Gomaa IEO, ElMeshad AN, et al. Distinct proteins in protein corona of nanoparticles represent a promising venue for endogenous targeting - part II: in vitro and in vivo kinetics study. *Int J Nanomed.* 2020;15:9539–9556. doi:10.2147/IJN.S273721
87. Gao J, Liu J, Xie F, Lu Y, Yin C, Shen X. Co-delivery of docetaxel and salinomycin to target both breast cancer cells and stem cells by PLGA/TPGS nanoparticles. *Int J Nanomed.* 2019;14:9199–9216. doi:10.2147/IJN.S230376
88. Li G, Zhao L. Sorafenib-loaded hydroxyethyl starch-TG100-115 micelles for the treatment of liver cancer based on synergistic treatment. *Drug Deliv.* 2019;26(1):756–764. doi:10.1080/10717544.2019.1642418
89. Hafizi M, Kalanaky S, Moaiery H, et al. A randomized, double-blind, placebo-controlled investigation of BCc1 nanomedicine effect on survival and quality of life in metastatic and non-metastatic gastric cancer patients. *J Nanobiotechnology.* 2019;17(1):52. doi:10.1186/s12951-019-0484-0
90. Cheng N, Watkins-Schulz R, Junkins RD, et al. A nanoparticle-incorporated STING activator enhances antitumor immunity in PD-L1-insensitive models of triple-negative breast cancer. *JCI Insight.* 2018;3(22):e120638. doi:10.1172/jci.insight.120638
91. Tang L, Fan TM, Borst LB, Cheng J. Synthesis and biological response of size-specific, monodisperse drug-silica nanoconjugates. *ACS Nano.* 2012;6(5):3954–3966. doi:10.1021/nn300149c
92. Oliveira TS, De Lima Silva V, Assunção LS, et al. A patent data analysis in nanotechnology applied to essential oils. *Recent Pat Nanotechnol.* 2022;16(2):92–106. doi:10.2174/1872210515666210217090541
93. Delbreil P, Rabanel JM, Banquy X, Brambilla D. Therapeutic nanotechnologies for Alzheimer’s disease: a critical analysis of recent trends and findings. *Adv Drug Deliv Rev.* 2022;187:114397. doi:10.1016/j.addr.2022.114397
94. Enescu D, Cerqueira MA, Fucinos P, Pastrana LM. Recent advances and challenges on applications of nanotechnology in food packaging. A literature review. *Food Chem Toxicol.* 2019;134:110814. doi:10.1016/j.fct.2019.110814
95. Akinc A, Maier MA, Manoharan M, et al. The Onpatro story and the clinical translation of nanomedicines containing nucleic acid-based drugs. *Nat Nanotechnol.* 2019;14(12):1084–1087. doi:10.1038/s41565-019-0591-y

96. Karp JM, Peer D. Focus on RNA interference: from nanoformulations to in vivo delivery. *Nanotechnology*. 2018;29(1):010201. doi:10.1088/1361-6528/aa98e3
97. Bian Q, Huang L, Xu Y, et al. A facile low-dose photosensitizer-incorporated dissolving microneedles-based composite system for eliciting antitumor immunity and the abscopal effect. *ACS Nano*. 2021;15(12):19468–19479. doi:10.1021/acsnano.1c06225
98. Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. *Nat Rev Drug Discov*. 2021;20(2):101–124. doi:10.1038/s41573-020-0090-8
99. Leonard RC, Williams S, Tulpule A, Levine AM, Oliveros S. Improving the therapeutic index of anthracycline chemotherapy: focus on liposomal doxorubicin (Myocet). *Breast*. 2009;18(4):218–224. doi:10.1016/j.breast.2009.05.004
100. Burkin MA, Surovov YA, Arzumanyan VG, Galvis IA. Development and application of amphotericin B immunoassay for pharmacokinetic studies and therapeutic drug monitoring in critically ill patients. *J Pharm Biomed Anal*. 2022;218:114875. doi:10.1016/j.jpba.2022.114875
101. Partikel K, Korte R, Stein NC, et al. Effect of nanoparticle size and PEGylation on the protein Corona of PLGA nanoparticles. *Eur J Pharm Biopharm*. 2019;141:70–80. doi:10.1016/j.ejpb.2019.05.006
102. Singh N, Manshian B, Jenkins GJ, et al. NanoGenotoxicology: the DNA damaging potential of engineered nanomaterials. *Biomaterials*. 2009;30(23–24):3891–3914. doi:10.1016/j.biomaterials.2009.04.009
103. Smolkova B, Dusinska M, Gabelova A. Nanomedicine and epigenome. Possible health risks. *Food Chem Toxicol*. 2017;109(Pt 1):780–796. doi:10.1016/j.fct.2017.07.020
104. Manke A, Wang L, Rojanasakul Y. Mechanisms of nanoparticle-induced oxidative stress and toxicity. *Biomed Res Int*. 2013;2013:942916. doi:10.1155/2013/942916
105. Goh XX, Tang PY, Tee SF. Effects of antipsychotics on antioxidant defence system in patients with schizophrenia: a meta-analysis. *Psychiatry Res*. 2022;309:114429. doi:10.1016/j.psychres.2022.114429
106. Cary CM, Seymore TN, Singh D, et al. Single inhalation exposure to polyamide micro and nanoplastic particles impairs vascular dilation without generating pulmonary inflammation in virgin female Sprague Dawley rats. *Part Fibre Toxicol*. 2023;20(1):16. doi:10.1186/s12989-023-00525-x
107. Cruces E, Barrios AC, Cahue YP, Januszewski B, Gilbertson LM, Perreault F. Similar toxicity mechanisms between graphene oxide and oxidized multi-walled carbon nanotubes in *Microcystis aeruginosa*. *Chemosphere*. 2021;265:129137. doi:10.1016/j.chemosphere.2020.129137
108. Li Y, Wang WX. Uptake, intracellular dissolution, and cytotoxicity of silver nanowires in cell models. *Chemosphere*. 2021;281:130762. doi:10.1016/j.chemosphere.2021.130762
109. Sun H, Jiang C, Wu L, Bai X, Zhai S. Cytotoxicity-related bioeffects induced by nanoparticles: the role of surface chemistry. *Front Bioeng Biotechnol*. 2019;7:414. doi:10.3389/fbioe.2019.00414
110. Shi Y, Lammers T. Combining nanomedicine and immunotherapy. *Acc Chem Res*. 2019;52(6):1543–1554. doi:10.1021/acs.accounts.9b00148
111. Troelnikov A, Perkins G, Yuson C, et al. Basophil reactivity to BNT162b2 is mediated by PEGylated lipid nanoparticles in patients with PEG allergy. *J Allergy Clin Immunol*. 2021;148(1):91–95. doi:10.1016/j.jaci.2021.04.032
112. Muhammad Q, Jang Y, Kang SH, Moon J, Kim WJ, Park H. Modulation of immune responses with nanoparticles and reduction of their immunotoxicity. *Biomater Sci*. 2020;8(6):1490–1501. doi:10.1039/c9bm01643k
113. Duvic M, Talpur R. Optimizing denileukin diftiox (Ontak) therapy. *Future Oncol*. 2008;4(4):457–469. doi:10.2217/14796694.4.4.457
114. Halwani AA. Development of pharmaceutical nanomedicines: from the bench to the market. *Pharmaceutics*. 2022;14(1):106. doi:10.3390/pharmaceutics14010106
115. Choi YH, Han HK. Nanomedicines: current status and future perspectives in aspect of drug delivery and pharmacokinetics. *J Pharm Investig*. 2018;48(1):43–60. doi:10.1007/s40005-017-0370-4
116. Schlichte L, Setji N, Walter J, et al. The use of templates for documenting advance care planning conversations: a descriptive analysis. *J Pain Symptom Manage*. 2023;66(2):123–136. doi:10.1016/j.jpainsymman.2023.04.015
117. Albalawi F, Hussein MZ, Fakurazi S, Masarudin MJ. Engineered nanomaterials: the challenges and opportunities for nanomedicines. *Int J Nanomed*. 2021;16:161–184. doi:10.2147/IJN.S288236
118. Cáceres C, Heusser B, Garnham A, Moczko E. The major hypotheses of alzheimer's disease: related nanotechnology-based approaches for its diagnosis and treatment. *Cells*. 2023;12(23):2669. doi:10.3390/cells12232669
119. Godoy-Gallardo M, Eckhard U, Delgado LM, et al. Antibacterial approaches in tissue engineering using metal ions and nanoparticles: from mechanisms to applications. *Bioact Mater*. 2021;6(12):4470–4490. doi:10.1016/j.bioactmat.2021.04.033
120. Farjadian F, Ghasemi A, Gohari O, Rooftan A, Karimi M, Hamblin MR. Nanopharmaceuticals and nanomedicines currently on the market: challenges and opportunities. *Nanomedicine*. 2019;14(1):93–126. doi:10.2217/nmm-2018-0120
121. Anselmo AC, Mitragotri S. Nanoparticles in the clinic: an update. *Bioeng Transl Med*. 2019;4(3):e10143. doi:10.1002/btm2.10143
122. Sun Y, Lu Y, Yin L, Liu Z. The roles of nanoparticles in stem cell-based therapy for cardiovascular disease. *Front Bioeng Biotechnol*. 2020;8:947. doi:10.3389/fbioe.2020.00947
123. Selvarajan V, Obuobi S, Ee PLR. Silica nanoparticles—a versatile tool for the treatment of bacterial infections. *Front Chem*. 2020;8:602. doi:10.3389/fchem.2020.00602
124. Ezhilarasu H, Vishalli D, Dheen ST, Bay BH, Srinivasan DK. Nanoparticle-based therapeutic approach for diabetic wound healing. *Nanomaterials (Basel)*. 2020;10(6):1234. doi:10.3390/nano10061234
125. Burduşel AC, Gherasim O, Andronescu E, Grumezescu AM, Ficai A. Inorganic nanoparticles in bone healing applications. *Pharmaceutics*. 2022;14(4):770. doi:10.3390/pharmaceutics14040770
126. Zadeh Mehrizi T, Shafiee Ardestani M. Application of non-metal nanoparticles, as a novel approach, for improving the stability of blood products: 2011–2021. *Prog Biomater*. 2022;11(2):137–161. doi:10.1007/s40204-022-00188-5
127. Dykman LA. Gold nanoparticles for preparation of antibodies and vaccines against infectious diseases. *Expert Rev Vaccines*. 2020;19(5):465–477. doi:10.1080/14760584.2020.1758070
128. Böttger R, Pauli G, Chao PH, Al Fayed N, Hohenwarter L, Li SD. Lipid-based nanoparticle technologies for liver targeting. *Adv Drug Deliv Rev*. 2020;154–155:79–101. doi:10.1016/j.addr.2020.06.017
129. Madawi EA, Al Jayoush AR, Rawas-Qalaji M, et al. Polymeric nanoparticles as tunable nanocarriers for targeted delivery of drugs to skin tissues for treatment of topical skin diseases. *Pharmaceutics*. 2023;15(2):657. doi:10.3390/pharmaceutics15020657

130. Tsung TH, Tsai YC, Lee HP, Chen YH, Lu DW. Biodegradable polymer-based drug-delivery systems for ocular diseases. *Int J Mol Sci.* 2023;24(16):12976. doi:10.3390/ijms241612976
131. Hua S, de Matos MBC, Metselaar JM, Storm G. Current trends and challenges in the clinical translation of nanoparticulate nanomedicines: pathways for translational development and commercialization. *Front Pharmacol.* 2018;9:790. doi:10.3389/fphar.2018.00790
132. Gaspar R, Duncan R. Polymeric carriers: preclinical safety and the regulatory implications for design and development of polymer therapeutics. *Adv Drug Deliv Rev.* 2009;61(13):1220–1231. doi:10.1016/j.addr.2009.06.003
133. Conde J, Artzi N. Are RNAi and miRNA therapeutics truly dead? *Trends Biotechnol.* 2015;33(3):141–144. doi:10.1016/j.tibtech.2014.12.005
134. DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: new estimates of R&D costs. *J Health Econ.* 2016;47:20–33. doi:10.1016/j.jhealeco.2016.01.012
135. Hare JI, Lammers T, Ashford MB, Puri S, Storm G, Barry ST. Challenges and strategies in anti-cancer nanomedicine development: an industry perspective. *Adv Drug Deliv Rev.* 2017;108:25–38. doi:10.1016/j.addr.2016.04.025
136. Farokhzad OC, Langer R. Impact of nanotechnology on drug delivery. *ACS Nano.* 2009;3(1):16–20. doi:10.1021/nn900002m
137. He X, Deng H, Hwang HM. The current application of nanotechnology in food and agriculture. *J Food Drug Anal.* 2019;27(1):1–21. doi:10.1016/j.jfda.2018.12.002
138. Alzate-Correa D, Lawrence WR, Salazar-Puerta A, Higuera-Castro N, Gallego-Perez D. Nanotechnology-driven cell-based therapies in regenerative medicine. *AAPS J.* 2022;24(2):43. doi:10.1208/s12248-022-00692-3
139. Rabiee N, Ahmadi S, Fatahi Y, et al. Nanotechnology-assisted microfluidic systems: from bench to bedside. *Nanomedicine.* 2021;16(3):237–258. doi:10.2217/nnm-2020-0353
140. Mansouri V, Beheshtizadeh N, Gharibshahian M, Sabouri L, Varzandeh M, Rezaei N. Recent advances in regenerative medicine strategies for cancer treatment. *Biomed Pharmacother.* 2021;141:111875. doi:10.1016/j.biopha.2021.111875
141. Boulaiz H, Alvarez PJ, Ramirez A, et al. Nanomedicine: application areas and development prospects. *Int J Mol Sci.* 2011;12(5):3303–3321. doi:10.3390/ijms12053303
142. Hull SM, Brunel LG, Heilshorn SC. Bioprinting of cell-laden hydrogels for improved biological functionality. *Adv Mater.* 2022;34(2):e2103691. doi:10.1002/adma.202103691
143. Zimmermann R, Vieira Alves Y, Sperling LE, Pranke P. Nanotechnology for the treatment of spinal cord injury. *Tissue Eng Part B Rev.* 2021;27(4):353–365. doi:10.1089/ten.TEB.2020.0188

Drug Design, Development and Therapy

Dovepress

Publish your work in this journal

Drug Design, Development and Therapy is an international, peer-reviewed open-access journal that spans the spectrum of drug design and development through to clinical applications. Clinical outcomes, patient safety, and programs for the development and effective, safe, and sustained use of medicines are a feature of the journal, which has also been accepted for indexing on PubMed Central. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/drug-design-development-and-therapy-journal>